infections in a general hospital: characteristics and outcomes

G. Samonis, E. K. Vouloumanou, M. Christofaki, D. Dimopoulou, S. Maraki, E. Triantafyllou, D. P. Kofteridis, M. E. Falagas

► To cite this version:

G. Samonis, E. K. Vouloumanou, M. Christofaki, D. Dimopoulou, S. Maraki, et al.. infections in a general hospital: characteristics and outcomes. *European Journal of Clinical Microbiology and Infectious Diseases*, 2011, 30 (5), pp.653-660. 10.1007/s10096-010-1135-4 . hal-00658170

HAL Id: hal-00658170

<https://hal.science/hal-00658170>

Submitted on 10 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

***Serratia* infections in a general hospital: characteristics and outcomes**

George Samonis, MD, PhD,¹ Evridiki K. Vouloumanou, MD,² Maria Christofaki, MD,¹
Dimitra Dimopoulou, MD,¹ Sofia Maraki, MD,³ Eirini Triantafyllou,^{2,4}
Diamantis P. Kofteridis, MD,^{1,2}, Matthew E. Falagas, MD, MSc, DSc,^{2,5,6}

1. Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece

2. Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

3. Department of Clinical Microbiology, University Hospital of Heraklion, Heraklion, Crete, Greece

4. National Technical University of Athens, Athens, Greece

5. Department of Medicine, Henry Dunant Hospital, Athens, Greece

6. Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA

Corresponding author: Matthew E. Falagas, MD, MSc, DSc

Alfa Institute of Biomedical Sciences (AIBS),

9 Neapoleos Street, 151 23 Marousi, Athens, Greece

Tel: +30 (694) 611-0000

Fax: +30 (210) 683-9605

E-mail: m.falagas@aibs.gr

Running title: *Serratia* infections in a general hospital

Conflict of interest: None

Funding: None

Word count: abstract: 199, text: 2393

Number of tables: 3

Number of references: 52

Abstract

Objective We aimed to present our experience regarding infections caused by *Serratia* spp. in a region with relatively high antimicrobial resistance rates.

Methods We retrospectively reviewed the databases of the microbiological laboratory of the University hospital of Heraklion, Crete (2/2004-12/2009).

Results A total of 77 patients [67.5% men, mean age $\pm$ standard deviation (SD)= 56.9 $\pm$ 24.5 years) were identified; 37.7% were outpatients. Sixty-five (84.4%) of the 77 included patients had a *Serratia marcescens* isolate; the remaining 12 patients had a non-marcescens *Serratia* spp. The most frequently observed infections were respiratory tract infection (32.5%) and keratitis/endophthalmitis (20.8%). Seventy-three (94.9%) patients were cured. Four deaths were observed; 3 of them were considered as attributed to the *Serratia* infection. No difference was found regarding the characteristics and outcomes between patients with *Serratia marcescens* and non-marcescens infections. In addition, antipseudomonal penicillins, as well as their combinations with beta-lactamase inhibitors, carbapenems, and fluoroquinolones exhibited high antimicrobial activity against both the tested *Serratia marcescens* and non-marcescens isolates.

Conclusion Our study adds useful information regarding the characteristics and outcomes of patients with *Serratia* infection, as well as the susceptibilities of the respective *Serratia marcescens* and non-marcescens isolates, in a region with relatively high levels of antimicrobial resistance.

Keywords: Enterobacteriaceae, *Serratia liquefaciens*, *Serratia rubidaea*, beta-lactamase, nosocomial infection

Introduction

Serratia spp, particularly *Serratia marcescens*, are mainly encountered as causative pathogens of nosocomial infections and nosocomial outbreaks.^{1, 2} Specifically, *Serratia* spp. are incriminated for outbreaks in neonatal intensive care units (NICUs).³⁻⁵ In addition, due to their ability of biofilm formation and the production of enzymes including gelatinase, elastase and alkaline protease, *Serratia* spp. manage to invade human corneal epithelial cells and cause keratitis, and particularly contact lens-related keratitis.^{6, 7}

Even though *Serratia* spp. are mainly considered nosocomial pathogens, recently published population-based studies suggested that a considerable percentage of the identified *Serratia* infections is community-acquired.^{6, 8} Even though *Serratia marcescens* accounts for the majority of the identified *Serratia* isolates, many reports regarding infections and outbreaks caused from *Serratia* spp. other than *Serratia marcescens*, also appeared in the literature.^{7, 9-12} In addition, another issue that intensified the importance of *Serratia* infections is the emergence of multi-drug resistant *Serratia* isolates, and particularly extended spectrum beta-lactamase producing *Serratia* isolates (ESBLs).¹³⁻¹⁵

In this regard, the aim of our study was to present our experience regarding the characteristics and outcomes of patients with infections caused from *Serratia* spp. at a university hospital of a region with relatively high levels of antimicrobial resistance.¹⁶⁻²⁰

Methods

Study design and patient population

We present a descriptive study, based on the retrospective evaluation of a case series. Specifically, we retrospectively reviewed the databases of the microbiological laboratory of the University hospital of Heraklion, Crete in order to identify patients from whom *Serratia* spp. were isolated, during a 5-year period (February 2004-December 2009). The University hospital of Heraklion, Crete, is a 650-bed tertiary care centre, serving a population of approximately 650.000 individuals, with approximately 65.000-70.000 admitted patients/year. The following data were retrieved from the available medical records of the respective patients: sex, age, department of hospitalization, potential risk factors for acquisition of nosocomial infections (including immunosuppression, treatment with corticosteroids, malnutrition, trauma, surgery, and

presence of a urinary catheter), type of *Serratia* infection, antibiotic treatment administered for the infection, duration of hospitalization, as well as the outcome of the infection.

With regard to the evaluated potential risk factors in particular, the objective criteria of *malnutrition* were a BMI<18.5, or unintentional weight loss of more than 5% in the last month, or more than 10% in the last 6 months, whereas *trauma* was defined as any injury or wound infection. When more than one *Serratia* isolates were identified from a patient, we selected the 1st isolate for inclusion in our study. Moreover, we retrieved data regarding any other pathogens were simultaneously identified from the same clinical specimen.

Microbiological testing

The identification of the isolates was performed with the use of standard biochemical methods, the API 20 E system and the Vitek2 automated system (BioMérieux, Marcy l'Etoile, France).²¹ The antimicrobial susceptibility of the tested isolates to the evaluated antibiotic agents was determined by using the Vitek2 system and the results were interpreted according to CLSI criteria.²²

Statistical analysis

We performed comparisons regarding demographic and clinical characteristics between the included patients with a clinical specimen that yielded a *Serratia marcescens* isolate and those with a clinical specimen that yielded a *Serratia* spp. isolate (other than *Serratia marcescens*). The χ^2 test or the Fisher exact tests were used, when appropriate, in the comparisons regarding categorical variables, whereas the t-test was used in the comparisons regarding continuous variables. For non-normally distributed continuous variables, the Mann-Whitney signed-rank test was used. A p value of <0.05 was regarded as indicative of statistical significance. The comparisons were performed with the use of the OpenEpi Software,²³ and the SPSS software version 13.0 (SPSS Inc, Chicago, Illinois, USA).

Results

Patient characteristics

A total of 77 patients were identified as having a clinical specimen that yielded a *Serratia* spp. isolate during the study period. Detailed data regarding the demographic

and clinical characteristics of the included patients are presented in Table 1. Specifically, the mean age $\pm$ standard deviation (SD) of the included patients was 56.9 $\pm$ 24.5 years. Two of the 77 included patients were infants (7 and 8 months, respectively). The majority (67.5%) of the included patients were men. Regarding the department of hospitalization, the majority (59.7%) of the included patients were admitted in medical wards, whereas a percentage of 37.7% were outpatients. Seventeen (22.1%) of the 77 included patients did not have any comorbidity. Regarding the remaining 60 patients, cardiac diseases were reported most frequently (42.9%). A percentage of 32.5% of the included patients were immunosuppressed, 24.7% were treated with corticosteroids, 19.5% had undergone surgery, 13% had a urinary catheter, 9.1% were trauma-patients, and 7.8% were malnourished. In addition, 10 of the evaluated patients were admitted in the ICU; 2 of them on mechanical ventilation. No patient had a central venous catheter.

Infections and outcomes

A percentage of 32.5% of the included patients had a respiratory tract infection, followed by a 20.8% that had keratitis/endophthalmitis. None of the latter ocular infections was hospital-acquired. Other types of infections observed were skin and soft tissue infections (16.9%), urinary tract infections (13.0%), sepsis (6.5%), and cholecystitis (3.9%). In addition, 8 (10.4%) of the included patients were considered as colonized with *Serratia* spp. With regard to the patients' outcomes, 73 (94.9%) of the 77 included patients were cured. Four deaths were observed during hospitalization in our case series. Three of the 4 deceased patients had monomicrobial *Serratia* infections, whereas the remaining 1 patient had also an infection due to *Citrobacter freundii*. The 4 deaths were evaluated by the clinicians that took care of the specific patients as well as the study investigators. Three of these 4 deaths were considered as occurring due to the *Serratia* infection and 1 to other causes.

Comparisons regarding patient subpopulations

Comparative data regarding the included patients providing a clinical specimen that yielded a *Serratia marcescens* isolate and those with a clinical specimen that yielded a *Serratia* spp. isolate (other than *Serratia marcescens*) are also presented in Table 1. No difference was found between the compared patient sub-populations regarding the analyzed characteristics and outcomes.

Microbiological characteristics

Types of isolates and sites of isolation

In Table 2 we present data regarding the isolated *Serratia* spp, the respective sites of isolation, as well as any other simultaneously isolated non-*Serratia* species. Specifically, 65 (84.4%) of the 77 included patients had a *Serratia marcescens* isolate, whereas the remaining 12 patients had a non-marcescens *Serratia* spp. These were: *Serratia liquefaciens* in 5 patients; *Serratia rubidaea*: 3; *Serratia fonticola*: 2; *Serratia plymuthica*: 1 and *Serratia ficaria*: 1 patient. Detailed data regarding the respective sites of isolation are presented in Table 2. Other isolates, including *P. aeruginosa*, *K. pneumoniae*, and *Candida* spp., were identified concurrently to the isolation of the *Serratia* spp. Detailed data regarding the distribution of the concurrently isolated species are also presented in Table 2.

Antimicrobial susceptibility of the tested isolates

The susceptibility rates of the isolated *Serratia* spp. to the 30 analyzed antimicrobial agents are presented in Table 3. Regarding the isolated *Serratia marcescens*, that constituted the majority [65/77 (84.4 %)] of the identified *Serratia* isolates, the following antibiotic agents exhibited substantial antimicrobial activity against the tested isolates (72%-100% of the tested isolates were found susceptible): antipseudomonal penicillins (specifically, ticarcillin, piperacillin, and ceftazidime), ticarcillin-clavulanic acid, piperacillin-tazobactam, 3rd generation cephalosporins (cefotaxime and ceftriaxone), carbapenems (imipenem and meropenem), aztreonam, tobramycin, netilmicin, nitrofurantoin, and quinolones (specifically, pefloxacin, ofloxacin, norfloxacin, and ciprofloxacin).

Regarding the 12 tested non-marcescens *Serratia* spp., all of them were found susceptible to the following antimicrobial agents: ticarcillin, piperacillin, ticarcillin-clavulanic acid, piperacillin-tazobactam, ceftazidime, ceftriaxone, cefotaxime, imipenem, meropenem, aztreonam, tobramycin, netilmicin, nitrofurantoin, pefloxacin, ofloxacin, norfloxacin, and ciprofloxacin. In addition, amikacin, gentamicin, and chloramphenicol exhibited substantial antimicrobial activity against the 12 tested isolates (83.3% each).

Discussion

A total of 77 patients providing a clinical specimen that yielded a *Serratia* spp. isolate, were identified in a 700-bed tertiary care hospital during a 5-year period. The majority of the *Serratia* isolates were identified in male patients. This observation is in accordance with the findings of recent population-based studies, in which males were considered to be at higher risk for the acquisition of a *Serratia* isolate.⁸ In addition, ICU patients were represented by rather low percentages (13%) in this cohort, whereas a considerable percentage (38%) of the included patients were outpatients. Indeed, population-based studies also reported that the majority of the isolated *Serratia* species,⁸ including a considerable percentage of *Serratia* bacteremic episodes were of community onset.²⁴

With regard to the observed *Serratia* infections, these were mostly respiratory tract infections, followed by ocular infections, including keratitis and/or endophthalmitis, skin and soft tissue infections, and urinary tract infections. Indeed, due to their ability for biofilm formation, based on the interaction of quorum sensing system and nutrient factors,^{25, 26} *Serratia* spp frequently colonize medical devices, such as bronchoscopes,²⁷ urinary catheters,²⁸ water supplies,²⁹ whereas long-term carriage in the hands of healthcare workers has been reported, as well.³⁰ Consequently, *Serratia* spp are frequently incriminated for hospital-acquired bacteremias nosocomial respiratory and urinary tract infections, and nosocomial outbreaks.³¹⁻³⁴ Specifically, 13% of the included patients had a urinary catheter. In addition, due to the production of specific enzymes such as gelatinase, elastase and alkaline protease, *Serratia* spp. cause ocular infections including ulcerative keratitis, particularly contact lens-related keratitis,^{6, 35} and endophthalmitis.^{36, 37} Moreover, immunocompromised patients are considered more prone to *Serratia* infections. Of note, a considerable percentage of 32.5% of the included patients were immunosuppressed, and an additional 24.7% received corticosteroids.

Serratia marcescens is the most frequently isolated *Serratia* spp. However, other *Serratia* spp. including *Serratia liquefaciens*, *Serratia plymuthica*, and *Serratia rubidaea*, are recently identified as the cause of *Serratia* nosocomial infections and outbreaks.^{10, 12, 38, 39} Furthermore, non-marcescens *Serratia* spp are also incriminated for community-acquired infections.⁴⁰ A possible explanation that has been proposed for the relative scarcity of published evidence regarding non-marcescens *Serratia* spp. compared to *Serratia marcescens* is the misidentification of these specific strains by

commercially available identification systems.⁴¹ In our study, 12 (15.5%) of the 77 included patients provided a clinical specimen that non-marcescens *Serratia* spp (specifically, *Serratia liquefaciens*, *Serratia rubidaea*, *Serratia fonticola*, *Serratia plymuthica*, and *Serratia ficaria*). The majority of the respective infections were respiratory tract infections. Its worth to note that in the comparisons between the patient subpopulations with *S. marcescens* infection and those with non-marcescens *Serratia* infection, no difference was found regarding the demographical characteristics, comorbidity, risk-factors, types of infections, as well as infection outcomes.

As far as mortality is concerned, 4 of the 77 included patients died. Three of these 4 deaths were considered to have been probably attributed to the *Serratia* infection, after a meticulous evaluation of the respective clinical data from the clinicians as well as the study investigators. Regarding mortality from *Serratia* infections, published evidence report percentages of 5% and 37% for *Serratia* bacteremia 7-day and 6-months mortality, respectively.²⁴ However, mortality can occur even in less severe *Serratia* infections, such as urinary tract infections. Specifically, female gender and the development of secondary *S. marcescens* bacteremia have been identified as risk factors independently associated with fatality in patients with urinary tract infection due to *S. marcescens*.⁴² Moreover, the emergence of ESBL-producing *Serratia* spp. intensifies the importance of the issue of *Serratia* infection-related mortality. Specifically, a 30-day mortality rate of 33% has been reported for nosocomial patients with ESBL-producing *S. marcescens* infections.⁴³

Serratia spp. exhibit considerable antimicrobial resistance to penicillins and cephalosporins. This is mainly attributed to the fact that AmpC beta-lactamases are encoded in the chromosome of *Serratia* spp. The expression of these genes is inducible in most cases.^{44, 45} In our study all the 65 tested *Serratia marcescens* isolates were found resistant to amoxicillin and amoxicillin/clavulanic acid. Similarly, 1 of the 12 non-marcescens *Serratia* spp was susceptible to the above drugs. This observation was consistent regarding cefalothin, a 1st generation cephalosporin, whereas regarding cefuroxime, lower susceptibility rates were observed for the tested *Serratia marcescens* compared to the non-marcescens isolates. Additionally, a 35% of the tested *Serratia marcescens* isolates and a 50% of the non-marcescens isolates were found susceptible to cefoxitin. Finally, 3rd generation cephalosporins (ceftazidime and cefotaxime) and

ceftriaxone exhibited high susceptibility rates regarding the *Serratia marcescens* and non-marcescens tested isolates (95.4% and 100%, respectively).

On the other, other beta-lactamases, including CTX-M3, IMP-type, as well as TEM-type have also been identified in *Serratia* spp.^{14, 46-48} Specifically, the issue of the emergence of carbapenem resistance *Serratia* strains is of major importance. In our study, both imipenem and meropenem exhibited high antimicrobial activity rates against the tested *Serratia marcescens* and non-marcescens isolates. In addition, among the evaluated antimicrobial agents, tobramycin, netilmicin, nitrofurantoin, as well as the combination of trimethoprim with sulfonamides were also found highly active against the tested *Serratia marcescens* and non-marcescens isolates. On the contrary, amikacin and gentamicin were found to be more active against the tested non-marcescens isolates (83%) compared to the tested *Serratia marcescens* isolates. Finally, fluoroquinolones were also highly active against the tested *Serratia marcescens* and non-marcescens isolates. However, evidence regarding the chromosome-encoded resistance to fluoroquinolones of *Serratia marcescens* has appeared in the literature.⁴⁹⁻⁵¹

Our study has specific limitations that should be considered. Firstly, one should bear in mind the intrinsic methodological limitations of retrospective cohort studies before the extrapolation of the study findings. In addition, our findings derive from the evaluation of the clinical and microbiological data of a rather limited number of 77 patients that provided a clinical specimen that yielded a *Serratia* spp. isolate. Moreover, since *Serratia* spp. are often incriminated for nosocomial epidemics, one may consider that the *Serratia* strains included in this study are epidemic strains. Yet, even though genetic identification techniques were not used in this study, the 5-year study period is rather contradictory to the potential of a concurrent nosocomial epidemic. However, one may consider that a proportion of the tested *Serratia* isolates might have been of the same clonal origin. Finally, even though the emergence of ESBL-producing *Serratia* spp. appears to be an issue of increasing importance, microbiological methods for the identification of ESBL-producing isolates, among the evaluated *Serratia* isolates, were also not implemented in this study.

In conclusion, our study aids in the clarification of issues regarding the characteristics and outcomes of patients with *Serratia* infections, as well as regarding the susceptibility patterns of the respective isolates. In the era of alarmingly high antimicrobial resistance,

and particularly in the era of ESBL-producing enterobacteriaceae,⁵² our findings may provide useful information regarding the infections caused from this specific pathogen, as they derive from a clinical setting with relatively high levels of antimicrobial resistance.

Reference list

1. Chemaly RF, Rathod DB, Raad, II. A tertiary care cancer center experience of the 2007 outbreak of *Serratia marcescens* bloodstream infection due to prefilled syringes. *Infect Control Hosp Epidemiol* 2009;30:1237-8.
2. Kim JH, Choi WH, Yun SW, Chae SA, Yoo BH. An Outbreak of *Serratia marcescens* Sepsis in a Pediatric Ward. *Clin Pediatr (Phila)* 2010.
3. Arslan U, Erayman I, Kirdar S, et al. *Serratia marcescens* sepsis outbreak in a neonatal intensive care unit. *Pediatr Int* 2010;52:208-12.
4. Dessi A, Puddu M, Testa M, Marcialis MA, Pintus MC, Fanos V. *Serratia marcescens* infections and outbreaks in neonatal intensive care units. *J Chemother* 2009;21:493-9.
5. Voelz A, Muller A, Gillen J, et al. Outbreaks of *Serratia marcescens* in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. *Int J Hyg Environ Health* 2010;213:79-87.
6. Pinna A, Usai D, Sechi LA, Carta A, Zanetti S. Detection of virulence factors in *Serratia* strains isolated from contact lens-associated corneal ulcers. *Acta Ophthalmol* 2009.
7. Szczotka-Flynn LB, Imamura Y, Chandra J, et al. Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. *Cornea* 2009;28:918-26.
8. Laupland KB, Parkins MD, Gregson DB, Church DL, Ross T, Pitout JD. Population-based laboratory surveillance for *Serratia* species isolates in a large Canadian health region. *Eur J Clin Microbiol Infect Dis* 2008;27:89-95.
9. Dalamaga M, Pantelaki M, Karmaniolas K, Matekovits A, Daskalopoulou K. Cutaneous abscess and bacteremia due to *Serratia ficaria*. *J Eur Acad Dermatol Venereol* 2008;22:1388-9.
10. Dubouix A, Roques C, Segonds C, et al. Epidemiological investigation of a *Serratia liquefaciens* outbreak in a neurosurgery department. *J Hosp Infect* 2005;60:8-13.
11. Grohskopf LA, Roth VR, Feikin DR, et al. *Serratia liquefaciens* bloodstream infections from contamination of epoetin alfa at a hemodialysis center. *N Engl J Med* 2001;344:1491-7.

333 12. Mostafa E, Mohammed F, Abdelhamid Z, Tahar B, Sakina E, Belkacem C. Septic
334 pseudarthrosis caused by *Serratia plymuthica*. *Joint Bone Spine* 2008;75:506-7.

335 13. Crivaro V, Bagattini M, Salza MF, et al. Risk factors for extended-spectrum beta-
336 lactamase-producing *Serratia marcescens* and *Klebsiella pneumoniae* acquisition in a
337 neonatal intensive care unit. *J Hosp Infect* 2007;67:135-41.

338 14. Mlynarczyk A, Szymanek K, Sawicka-Grzelak A, et al. CTX-M and TEM as
339 predominant types of extended spectrum beta-lactamases among *Serratia marcescens*
340 isolated from solid organ recipients. *Transplant Proc* 2009;41:3253-5.

341 15. Rizvi M, Fatima N, Shukla I, Malik A. Epidemiology of extended spectrum beta-
342 lactamases in *Serratia* and *Citrobacter* species in North India. *Indian J Pathol Microbiol*
343 2010;53:193-4.

344 16. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Kapaskelis A, Samonis
345 G. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. *Int*
346 *J Antimicrob Agents* 2010;35:497-9.

347 17. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E,
348 Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively
349 drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. *Int J Antimicrob*
350 *Agents* 2010;35:240-3.

351 18. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas
352 ME. Susceptibility of urinary tract bacteria to fosfomycin. *Antimicrob Agents*
353 *Chemother* 2009;53:4508-10.

354 19. Samonis G, Maraki S, Rafailidis PI, Kapaskelis A, Kastoris AC, Falagas ME.
355 Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and
356 other antimicrobials. *Future Microbiol* 2010;5:961-70.

357 20. Samonis G, Matthaïou DK, Kofteridis D, Maraki S, Falagas ME. In vitro
358 susceptibility to various antibiotics of colistin-resistant gram-negative bacterial isolates
359 in a general tertiary hospital in Crete, Greece. *Clin Infect Dis* 2010;50:1689-91.

360 21. Farmer III, JJ, Boatwright KD, Janda JM. Enterobacteriaceae: Introduction and
361 identification. In: Murray P, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors.
362 *Manual of clinical microbiology*, Ninth ed., Volume 1. Washington: American Society
363 for Microbiology; 2007. p. 649-669. .

364 22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial
365 susceptibility testing; Nineteenth informational supplement. CLSI Document M100-
366 S19. Wayne, PA, USA; 2009.

23. Dean, A., K. Sullivan, and M. Soe, OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.2.1. Updated 2008/04/06 [cited 2008/09/18]; Available from: www.OpenEpi.com.
24. Engel HJ, Collignon PJ, Whiting PT, Kennedy KJ. *Serratia* sp. bacteremia in Canberra, Australia: a population-based study over 10 years. *Eur J Clin Microbiol Infect Dis* 2009;28:821-4.
25. Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, Kjelleberg S. Biofilm formation and sloughing in *Serratia marcescens* are controlled by quorum sensing and nutrient cues. *J Bacteriol* 2005;187:3477-85.
26. Van Houdt R, Givskov M, Michiels CW. Quorum sensing in *Serratia*. *FEMS Microbiol Rev* 2007;31:407-24.
27. Molina-Cabrillana J, Rodriguez-Bermejo JC, del Rosario-Quintana C, Bolanos-Rivero M. [Rapid detection of an outbreak of bronchoscopy-associated colonization by *Serratia marcescens*]. *Enferm Infecc Microbiol Clin* 2007;25:222-4.
28. Jones GL, Muller CT, O'Reilly M, Stickler DJ. Effect of triclosan on the development of bacterial biofilms by urinary tract pathogens on urinary catheters. *J Antimicrob Chemother* 2006;57:266-72.
29. Horcajada JP, Martinez JA, Alcon A, et al. Acquisition of multidrug-resistant *Serratia marcescens* by critically ill patients who consumed tap water during receipt of oral medication. *Infect Control Hosp Epidemiol* 2006;27:774-7.
30. de Vries JJ, Baas WH, van der Ploeg K, Heesink A, Degener JE, Arends JP. Outbreak of *Serratia marcescens* colonization and infection traced to a healthcare worker with long-term carriage on the hands. *Infect Control Hosp Epidemiol* 2006;27:1153-8.
31. Casolari C, Pecorari M, Fabio G, et al. A simultaneous outbreak of *Serratia marcescens* and *Klebsiella pneumoniae* in a neonatal intensive care unit. *J Hosp Infect* 2005;61:312-20.
32. Johnson JS, Croall J, Power JS, Armstrong GR. Fatal *Serratia marcescens* meningitis and myocarditis in a patient with an indwelling urinary catheter. *J Clin Pathol* 1998;51:789-90.
33. Kim BN, Choi SI, Ryoo NH. Three-year follow-up of an outbreak of *Serratia marcescens* bacteriuria in a neurosurgical intensive care unit. *J Korean Med Sci* 2006;21:973-8.
34. Yu WL, Lin CW, Wang DY. *Serratia marcescens* bacteremia: clinical features and antimicrobial susceptibilities of the isolates. *J Microbiol Immunol Infect* 1998;31:171-9.

35. Parment PA. The role of *Serratia marcescens* in soft contact lens associated ocular infections. A review. *Acta Ophthalmol Scand* 1997;75:67-71.
36. Latorre G. Endogenous *Serratia marcescens* endophthalmitis in a preterm infant. *Indian J Pediatr* 2008;75:410.
37. Mah-Sadorra JH, Najjar DM, Rapuano CJ, Laibson PR, Cohen EJ. *Serratia* corneal ulcers: a retrospective clinical study. *Cornea* 2005;24:793-800.
38. Chuang TY, Chuang CP, Cheng HH, Hsueh PR. Aortic valve infective endocarditis caused by *Serratia liquefaciens*. *J Infect* 2007;54:e161-3.
39. Sekhsokh Y, Arsalane L, El Ouenass M, Doublali T, Bajjou T, Lahlou Amine I. [*Serratia rubidaea* bacteremia]. *Med Mal Infect* 2007;37:287-9.
40. Okada T, Yokota E, Matsumoto I. [Community acquired sepsis by *Serratia rubidaea*]. *Kansenshogaku Zasshi* 2002;76:109-12.
41. Anahory T, Darbas H, Ongaro O, Jean-Pierre H, Mion P. *Serratia ficaria*: a misidentified or unidentified rare cause of human infections in fig tree culture zones. *J Clin Microbiol* 1998;36:3266-72.
42. Liu J-W, Hsu Y-M, Huang Y-F. Independent prognostic factors for fatality in patients with urinary tract infection caused by *Serratia marcescens*. *Infect Control Hosp Epidemiol* 2004;25:80-2.
43. Cheng K-C, Chuang Y-C, Wu L-T, Huang G-C, Yu W-L. Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing *Serratia marcescens* at a medical center in Taiwan. *Jpn J Infect Dis* 2006;59:147-52.
44. Park YJ, Park SY, Oh EJ, et al. Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing *Enterobacter cloacae*, *Citrobacter freundii*, and *Serratia marcescens* in Korea and investigation of screening criteria. *Diagn Microbiol Infect Dis* 2005;51:265-9.
45. Rizvi M, Fatima N, Rashid M, et al. Extended spectrum AmpC and metallo-beta-lactamases in *Serratia* and *Citrobacter* spp. in a disc approximation assay. *J Infect Dev Ctries* 2009;3:285-94.
46. Kumamoto Y, Tsukamoto T, Matsukawa M, et al. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). I. Susceptibility distribution]. *Jpn J Antibiot* 2005;58:518-43.
47. Tsou MF, Yu WL, Hung SW, et al. Detection of cefotaxime-resistant CTX-M-3 in clinical isolates of *Serratia marcescens*. *Folia Microbiol (Praha)* 2004;49:452-6.
48. Zhao WH, Hu ZQ, Chen G, Matsushita K, Fukuchi K, Shimamura T. Characterization of imipenem-resistant *Serratia marcescens* producing IMP-type and

TEM-type beta-lactamases encoded on a single plasmid. Microbiol Res 2007;162:46-52.

49. Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 2002;43:141-7.

50. Acar JF, O'Brien TF, Goldstein FW, Jones RN. The epidemiology of bacterial resistance to quinolones. Drugs 1993;45 Suppl 3:24-8.

51. Velasco C, Rodriguez-Martinez JM, Briaies A, Diaz de Alba P, Calvo J, Pascual A. Smaqnr, a new chromosome-encoded quinolone resistance determinant in *Serratia marcescens*. J Antimicrob Chemother 2010;65:239-42.

52. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009;73:345-54.

Table 1. Baseline characteristics, infections and outcomes of the included patients.

	Mean ($\pm$ SD) or number (%)			
	All	<i>Serratia marcescens</i>	Other <i>Serratia</i> spp.	P value
		(Group A)	(non-marcescens)	(Group A vs Group B)
	n ₁ =77	n ₂ =65	n ₃ =12	
Number of patients				
Demographics				
Age (years)	56.9 $\pm$ 24.5	56.3 $\pm$ 24.5	59.9 $\pm$ 25.9	0.7
Sex (male)	52 (67.5)	45 (69.2)	7 (58.3)	0.7
Department of hospitalization				
Medical	46 (59.7)	38(58.5)	8 (66.7)	0.8
Surgical	13 (16.9)	11 (16.9)	2 (16.7)	>0.9
Pediatric	2 (2.9)	2 (3.1)	0	>0.9
ICU	10 (13.0)	10 (15.4)	0	0.3
Outpatients	29 (37.7)	25 (38.5)	4 (33.3)	>0.9
Transfer from another hospital	2 (2.9)	2 (3.1)	0 (0)	>0.9
Comorbidity				
None	17 (22.1)	13 (20.0)	4 (33.3)	0.5
Diabetes mellitus	12 (15.6)	9 (13.8)	3 (25.0)	0.6
Cardiac diseases	33 (42.9)	27 (41.5)	6 (50.0)	0.8
Pulmonary diseases	14 (18.2)	12 (18.5)	2 (16.7)	>0.9
Renal diseases	7 (9.1)	5 (7.7)	2 (16.7)	0.6
Hepatic diseases	2 (2.6)	2 (3.1)	0	>0.9
CNS diseases	11(14.3)	11 (16.9)	0	0.3
Orthopedic diseases	9 (11.7)	8 (12.3)	1 (8.3)	>0.9
Malignancies	14 (18.2)	11 (16.9)	3 (25.0)	0.8
Autoimmune diseases	6 (7.8)	4 (6.2)	2 (16.7)	0.5
Hyperuricaemia	3 (3.9)	2 (3.1)	1 (8.3)	0.8
Smoking	11 (14.3)	10 (15.4)	1 (8.3)	0.9
Bening prostate hyperplasia	5 (6.5)	4 (6.2)	1 (8.3)	>0.9
Lipofuscinosis	1 (1.3)	1 (1.5)	0	>0.9
Risk factors				
Corticosteroids	19 (24.7)	16 (24.6)	3 (25.0)	>0.9
Immunosuppression	25 (32.5)	19 (29.2)	6 (50.0)	0.3
Malnutrition	6 (7.8)	3 (4.6)	3 (25.0)	0.1
Urinary catheter	10 (13.0)	8 (12.3)	2 (16.7)	>0.9
Trauma	7 (9.1)	6 (9.3)	1 (8.3)	>0.9
Surgery	15 (19.5)	13 (20.0)	2 (16.7)	>0.9
Type of infection				
RTI	25 (32.5)	20 (30.8)	5 (41.7)	0.7
UTI	10 (13.0)	10 (15.4)	0	0.3
SSTI	13 (16.9)	9 (13.9)	4 (33.3)	0.2
Keratitis/endophthalmitis	16 (20.8)	14 (21.5)	2 (16.7)	>0.9
Cholecystitis	3 (3.9)	2 (3.1)	1 (8.3)	0.8
Sepsis	5 (6.5)	4 (6.2)	1 (8.3)	>0.9
Colonization	8 (10.4)	8(12.3)	0	0.5
Time to acquisition of the 1st positive culture for <i>Serratia</i> spp.	Median (range) [*] : 2 (0-158)	Median (range) ^{**} : 2 (0-158)	Median (range) ^{***} : 2 (0-5)	0.4
Duration of hospitalization (days)	Median (range) [*] : 6 (1-206)	Median (range) ^{**} : 7 (1-206)	Median (range) ^{***} : 5 (1-15)	0.3

Outcome				
Cure	73 (94.9)	61 (93.8)	12 (100)	0.9
Death	4 (5.2)	4 (6.2)	0 (0)	>0.9

Abbreviations: ICU: intensive care unit, CNS: central nervous system, RTI: respiratory tract infection, UTI:

urinary tract infections, SSTI: skin and soft tissue infection.

*: NR: 15/77 (19.2%)

**: NR: 12/65 (18.1%)

***: NR: 3/12 (25%)

Table 2. Data regarding the isolated species and sites of isolation.

Species identified

***Serratia* spp.**

<i>Serratia marcescens</i>	65 (84.4)
<i>Serratia liquefaciens</i>	5 (6.5)
<i>Serratia rubidaea</i>	3 (3.9)
<i>Serratia fonticola</i>	2 (2.6)
<i>Serratia plymuthica</i>	1 (1.3)
<i>Serratia ficaria</i>	1 (1.3)

Other species

<i>Staphylococcus</i> spp.	3 (3.9)
<i>Proteus vulgaris</i>	1 (1.3)
<i>Pseudomonas aeruginosa</i>	4 (5.2)
<i>Klebsiella pneumoniae</i>	1 (1.3)
<i>Candida</i> spp	2 (2.6)
<i>Escherichia coli</i>	1 (1.3)
<i>Enterococcus faecalis</i>	1 (1.3)
<i>Mycoplasma pneumoniae</i>	1 (1.3)
<i>Enterococcus faecalis</i>	1 (1.3)
<i>Citrobacter freundii</i>	1 (1.3)

Site of isolation

Blood	6 (7.8)
Urine	12 (15.6)
BAL	9 (11.7)
Bronchial secretions	8 (10.4)
Pharyngeal aspirate	3 (3.9)
Nasal aspirate	1 (1.3)
Sputum	7 (9.1)
Pus	13 (16.8)
Contact lens	9 (11.7)
Bile	3 (3.8)
Ocular aspirate	6 (7.8)
Conjunctiva	1 (1.3)
Yaloid pus	1 (1.3)
Tracheal tube	1 (1.3)

Number of positive cultures

One	70 (90.9)
Two	7 (9.1)

Abbreviations: BAL: bronchoalveolar lavage.

Table 3. Susceptibility patterns of *Serratia* isolates tested.

Antimicrobial agents	<i>Serratia marcescens</i> n ₁ =65		<i>Serratia</i> spp. (non-marcescens)* n ₂ =12		All <i>Serratia</i> isolates tested n=77	
	S (%)	I (%)	S (%)	I (%)	S (%)	I (%)
Ampicillin	0	0	1 (8.3)	0	1 (1.2)	0
Amoxicillin+Clavulanic acid	0	0	1 (8.3)	0	1 (1.2)	0
Ticarcillin	59 (90.8)	0	12 (100)	0	71 (92.2)	0
Ticarcillin+Clavulanic acid	61 (93.8)	1 (1.5)	12 (100)	0	73 (94.8)	1 (1.2)
Piperacillin	60 (92.3)	2 (3.1)	12 (100)	0	72 (96.0)	2 (2.5)
Piperacillin/tazobactam	62 (95.4)	0	12 (100)	0	74 (98.6)	0
Cefalothin	0	0	1 (8.3)	0	1 (1.2)	0
Cefuroxime	2 (3.1)	1 (1.5)	3 (25.0)	0	5 (6.4)	1 (1.2)
Cefoxitin	23 (35.4)	29 (44.6)	6 (50.0)	2 (16.7)	30 (38.9)	31 (40.2)
Cefotaxime	62 (95.4)	0	12 (100)	0	74 (98.6)	0
Ceftriaxone	62 (95.4)	0	12 (100)	0	74 (98.6)	0
Ceftazidime	62 (95.4)	0	12 (100)	0	74 (98.6)	0
Imipenem	62 (95.4)	0	12 (100)	0	74 (98.6)	0
Meropenem	64 (98.4)	0	12 (100)	0	76 (98.7)	0
Aztreonam	65 (100)	0	12 (100)	0	77 (100)	0
Tobramycin	60 (92.3)	2 (3.1)	12 (100)	0	72 (93.5)	2 (2.5)
Amikacin	34 (52.3)	5 (7.7)	10 (83.3)	0	44 (57.1)	5 (6.4)
Gentamicin	35 (53.8)	4 (6.2)	10 (83.3)	0	45 (58.4)	4 (5.1)
Netilmicin	58 (89.2)	2 (3.1)	12 (100)	0	71 (92.2)	2 (2.5)
Chloramphenicol	30/61 (49.2)**	5 (8.21)	10 (83.3)	0	40/73 (54.7)	5/73 (6.8)
Tetracycline	17/25 (68.0)***	3 (12.0)	3/3#	0	21/28 (75)	3/28 (10.7)
Trimethoprim	4 (6.2)	0	1 (8.3)	0	5 (6.4)	0
Trimethoprim+Sulfonamides	63 (96.9)	1 (1.5)	12 (100)	0	75 (97.4)	1 (1.2)
Nitrofurantoin	59 (90.7)	0	12 (100)	0	71 (92.2)	0
Nalidixic acid	4 (6.2)	1 (1.5)	1 (8.3)	2 (16.7)	5 (6.4)	3 (3.8)
Pefloxacin	60 (92.3)	0	12 (100)	0	72 (93.5)	0
Ofloxacin	62 (95.4)	1 (1.5)	12 (100)	0	74 (96.1)	1 (1.2)
Norfloxacin	63 (96.9)	0	12 (100)	0	75 (97.4)	0
Ciprofloxacin	63 (96.9)	0	12 (100)	0	75 (97.4)	0

Abbreviations: S: susceptibility, I: intermediate susceptibility, NR: Not Reported.

*: These include: *Serratia liquefaciens*: 5, *Serratia rubidaea*: 3, *Serratia fonticola*: 2, *Serratia plymuthica*: 1, *Serratia ficaria*: 1.

** : NR: 4/66 (6.1%)

***: NR: 40/66 (60.6%)

#: NR: 9/12 (75.0%)